ALMS: the cashflow

MyFinsight

For the quarter ending 2025-09-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net loss	-150,394	-39,642
Stock-based compensation	35,417	25,630
Net accretion of discounts on marketable securities	-3,876	-2,152
Depreciation and amortization	2,629	1,713
Non-cash lease expense	1,161	624
Gain on bargain purchase in connection with the acelyrin merger	187,907	187,907
Impairment of long-lived assets	529	-
Research and development prepaid expenses	-9,426	-7,373
Other prepaid expenses and other assets	-13,346	-96
Other assets, non-current	5,073	1,723
Accounts payable	-11,586	-1,162
Deferred revenue	1,944	2,611
Research and development accrued expenses	4,935	11,037
Other accrued expenses and current liabilities	2,554	6,537
Operating lease liabilities	-2,328	-1,349
Other liabilities, non-current	168	168
Deferred income tax liability	8,561	8,561
Net cash used in operating activities	-297,616	-186,707
Maturities of marketable securities	305,423	144,274
Purchases of marketable securities	161,648	24,535
Purchases of property and equipment	653	653
Cash, cash equivalents and restricted cash acquired in connection with the acelyrin merger	49,742	49,742
Net cash provided by (used in) investing activities	192,864	168,828
Repurchase of common stock shares issued upon early exercised restricted common stock	17	17
Proceeds from issuance of common stock under the 2024 espp	766	766
Net cash provided by financing activities	749	749
Net (decrease) increase in cash, cash equivalents and restricted cash	-104,003	-17,130
Cash and cash equivalents at beginning of period	170,632	-
Cash and cash equivalents at end of period	66,629	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

ALMS: the cashflow